Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase score

Abstract Background and Aim This retrospective study investigated the effect of 48‐week pemafibrate therapy in non‐alcoholic fatty liver disease (NAFLD) with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase (FAST) score. Methods A total of 31 NAFLD patients who were tre...

Full description

Bibliographic Details
Main Authors: Takeshi Hatanaka, Takashi Kosone, Naoto Saito, Satoshi Takakusagi, Hiroki Tojima, Atsushi Naganuma, Hitoshi Takagi, Toshio Uraoka, Satoru Kakizaki
Format: Article
Language:English
Published: Wiley 2021-10-01
Series:JGH Open
Subjects:
Online Access:https://doi.org/10.1002/jgh3.12650